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Predicting survival and therapy responses of breast cancer patients is a significant challenge. Two studies in this issue of 
Cancer Cell present a novel integrated analysis of genomic and transcriptomic profiles of 145 primary breast cancers and 51 
established cell lines. Data from clinical tumors highlighted mechanisms of disease and facilitated identification of potential 
therapeutic targets and prognostic biomarkers. An extensive well-characterized cancer cell line resource opens up opportunities 
to explore the determinants of cellular responses to existing and emerging therapies. Taken together, these studies illustrate how 
integrated molecular profiling may one day significantly impact diagnosis and therapeutic choice in human breast cancer.Since the early days of microarray technol-
ogy, numerous investigators have analyzed 
clinical cohorts of human breast cancers in 
order to better understand disease patho-
genesis, and to provide a molecular expla-
nation for the heterogeneity in the outcome 
and therapeutic response of breast cancer 
patients. A PubMed search identifies 827 
publications with the keywords “microarray” 
and “breast cancer.” Most of the research 
has focused on the characterization of tran-
scriptional profiles of breast cancer (Table 1). 
For example, Perou et al. (2000) and Sørlie 
et al. (2001) established the classification of 
breast tumors into five different phenotypic 
subtypes. van ’t Veer et al. (2002) and van 
de Vijver et al. (2002) divided breast can-
cer patients into those with favorable and 
unfavorable outcome with high accuracy, 
suggesting the potential of microarrays 
as a diagnostic test to select patients who 
would need adjuvant therapies. Many other 
studies have also identified gene signatures 
predictive of distant metastasis or survival 
(Wang et al., 2005; Naderi et al., 2006). 
Several authors have also studied profiles 
of genomic DNA copy numbers (Hicks et al., 
2005; Bergamaschi et al., 2006; Fridlyand 
et al., 2006) using array-based comparative 
genomic hybridization (CGH). These studies 
have identified numerous specific genetic 
alterations and have also defined subtypes 
of breast cancers at the genomic level.
Few of the previous studies have inte-
grated genomic and transcriptomics profiles 
from the same patient cohorts (Bergamaschi 
et al., 2006). This is a key contribution of cancer cell december 2006 the Chin et al. (2006) paper appearing in 
this issue of Cancer Cell. With 101 tumors 
comprehensively profiled at the DNA and 
RNA levels, the authors were able to better 
define the impact of specific genetic events 
on breast cancer phenotypes and clinical 
outcome. They indicate that genomic pro-
files provide additional prognostic informa-
tion as compared to what is available from 
transcriptomics profiling alone. For example, 
patients whose tumors had one or more 
DNA amplifications had a poor prognosis 
independently of the previously defined five 
major gene expression classes (Sørlie et al., 
2001). Interestingly, copy number imbal-
ance (i.e., any deviation from diploidy) may 
be prognostically important for a specific 
region at 8p11-p12. Integrative DNA/RNA 
microarray profiling may also suggest novel 
therapeutic opportunities. Chin et al. list nine 
potential therapeutic targets, which, like the prototype HER2 oncogene, are activated 
by recurrent gene amplifications in breast 
cancer and may show an association with 
aggressive tumor types. Many of these are 
potentially druggable by small-molecule 
inhibitors. For example, two potential amplifi-
cation targets, the GRB7 and PNMT genes, 
reside in the HER2 amplicon at 17q12 and 
are coactivated in breast cancer with HER2. 
Their targeting could provide synergistic 
therapeutic responses with Her2 inhibition 
or contribute to poor responses against 
Herceptin (Kao and Pollack, 2006).
Clinical tumor profiling is informative 
but at best associative in nature. In order 
to identify causative links between genes 
and tumor phenotypes, it is necessary to 
use cell lines. The Neve et al. (2006) paper 
describes the DNA and RNA microarray 
profiling data for a comprehensive resource 
of 51 different breast cancer cell lines, Table 1. Selected previous microarray profiling studies of human breast cancer
Publication No. of samples (gene expression) No. of samples (array-cGH)
chin et al., 2006 130 145
Neve et al., 2006 51 51
bergamaschi et al., 2006 89 89
Fridlyand et al., 2006 67
Hicks et al., 2005 101
Naderi et al., 2006 135
Perou et al., 2000 65
Sørlie et al., 2001 78
van ’t Veer et al., 2002 98
van de Vijver et al., 2002 295
Wang et al., 2005 286453
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the public domain. In contrast to the com-
monly expressed reservations among 
cancer researchers, as a group the breast 
cancer cell lines were found to be surpris-
ingly representative of the primary tumors. 
Although cell lines had a much higher num-
ber of genetic changes per sample than 
primary tumors, genetic events that were 
exclusively seen in the breast cancer cell 
lines were rare. As has been demonstrated 
with the extensively studied NCI-60 cancer 
cell line set (http://dtp.nci.nih.gov/index.
html), molecular profiles of cancer cell 
lines could help to identify pharmacoge-
nomic predictors of response to therapeu-
tic compounds. For example, Neve et al. 
(2006) treated cell lines with Herceptin and 
identified protein levels and genomic aber-
rations that were correlated with response 
and resistance. Indeed, if more cancer 
drug response data became available, this 
“UCB-51” set could be much more repre-
sentative and informative than the NCI-60 
data series for targeted exploration of thera-
peutic hypotheses in breast cancer.
As much as these two studies advance 
the field, there are also many important 
aspects that remain to be explored in the 
future. First of all, every clinical study is 
dependent on the patient selection and ther-
apies administered. These effects cannot be 
fully evaluated in retrospective studies. The 
present studies focused on amplifications, 
yet deletions and unbalanced translocations 
inactivating or activating cancer genes may 
also be important. As compared to the ?1 
Mb resolution of the BAC arrays used in 
these studies, the latest generation oligo-
array-based CGH can approach theoretical 
limits of about 10 kb across the nonrepeti-454 
Radiation biologists were the first to for-
mulate the concept of stem cells. The 
term “stem cell” was coined in the con-
Radiation resistance a
The concepts of stem cells being resistant 
ing to therapy followed by recurrence are w
CD133-expressing glioma cells in vivo and
the cell-cycle-regulating proteins CHK1/C
cells in their native environment within tum
and schedules for these patients.tive genomic DNA. Transcriptional profiling 
technologies also continue to advance. For 
example, alternatively spliced versions of 
genes are detectable with exon-level anal-
ysis, and detection of noncoding RNAs 
may pinpoint new information. The pres-
ent studies focused on genetic profiles, but 
epigenetic profiling has also been shown to 
be of significant importance. Metabolic and 
proteomic fingerprints as well as the math-
ematical analysis and modeling of all the 
“omics” data are needed to complete a com-
prehensive understanding of the molecular 
deregulation of the breast cancer cells in 
vitro and in vivo. Finally, taking molecular 
profiles toward the clinical diagnostic setting 
is the “final frontier” and will require stan-
dardized technologies, quality control, and 
prospective testing in large series of patient 
cohorts. This is a major effort for any single 
molecular profiling platform, and an enor-
mous challenge for the clinical application 
of integrated multiplatform profiling.
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